AOD-9604 results: what the human trial research actually shows

Last updated 2026-07-24

What is AOD-9604 and why was it developed for fat loss?

AOD-9604 is a synthetic fragment of human growth hormone, built from the C-terminal region (amino acids 176-191) that researchers identified as the piece responsible for HGH's fat-metabolizing effect, without the growth-promoting or blood-sugar effects of full-length HGH. The idea was simple and, on paper, elegant: isolate the part of the molecule that tells fat cells to release stored fat (lipolysis) and blocks new fat storage (anti-lipogenesis), and leave behind the parts that cause the joint swelling, insulin resistance, and organ growth people worry about with real growth hormone. That rationale is exactly why AOD-9604 got picked up by a biotech (originally Metabolic Pharmaceuticals in Australia) and pushed into obesity drug development in the early 2000s. A 2004 review in Current Opinion in Investigational Drugs covers this metabolic fragment approach directly, describing the compound's development as an anti-obesity candidate built on the fat-metabolizing domain of HGH ^[1]. The biochemistry is not make-believe. Fragmenting a hormone to isolate one activity is a legitimate drug design strategy, and it has worked for other molecules. The problem for AOD-9604 was never the theory. It was what happened when the fragment got tested in actual humans trying to lose weight. For background on the molecule itself, structure, and how it's classified today, see our aod 9604 peptide overview.

Did AOD-9604 pass human clinical trials for weight loss?

AOD-9604 went through Phase I and Phase IIb human trials for obesity, run by Metabolic Pharmaceuticals, and the results were not what a drug needs to reach approval. The company's own trial program is documented in the clinical trial registries and gateway summaries from the mid-2000s, including entries covering the drug pipeline of that era ^[2][3][4]. Here is the part that matters most for anyone considering this compound for fat loss: the weight-loss signal in the human obesity trials did not clearly separate from placebo. Some trial arms showed small differences in body weight or waist measurements, but the effect size was modest and the statistical picture across the program was not strong enough to convince regulators to move forward with an approval submission. A 2006 review of obesity drugs in clinical development, covering the competitive landscape AOD-9604 was part of, situates the compound among a crowded field of candidates that mostly did not make it to market ^[5]. This is the single most important fact in this entire article. AOD-9604 has never received FDA approval for obesity, for fat loss, or for any indication. You can check this yourself in the FDA's own approved drug database, Drugs@FDA, which lists every drug product ever approved in the United States ^[6]. AOD-9604 is not there, because it was never approved. The company that developed it eventually deprioritized the obesity program. There was no scandal, no safety catastrophe, just an underwhelming efficacy result that did not clear the bar needed to justify further Phase III investment and regulatory submission.

How strong is the placebo-separation problem, really?

When people say a trial "did not separate from placebo," it means the drug group and the sugar-pill group lost roughly similar amounts of weight, once you account for the fact that almost everyone in a diet-and-exercise trial loses some weight just from being watched, counseled, and put on a structured plan. This is not a small technical footnote. It is the whole ballgame in obesity drug development. Regulators do not approve a weight-loss drug because it beats zero. They approve it because it beats placebo by a clinically meaningful margin, typically several percentage points of body weight, sustained over many months, replicated across multiple trials. AOD-9604's Phase IIb data did not deliver that kind of separation. The available published record, including the clinical-trial gateway write-ups from 2003 and 2005 covering compounds in development at the time, does not report the kind of decisive placebo gap that other obesity therapies eventually produced ^[2][3][4]. That is a meaningfully different story from "AOD-9604 doesn't work at all," but it is also a very different story from "AOD-9604 is a proven fat-loss drug," which is how it often gets marketed online. An honest read of the data: there may be a real, small metabolic effect buried in there. There is not a large, reliable, reproducible fat-loss effect that would justify the confidence with which some sellers talk about this peptide.

Does AOD-9604 raise IGF-1 or affect blood sugar like HGH does?

One of the actual selling points of the fragment approach checked out reasonably well in early research: AOD-9604 was designed to avoid the diabetogenic and growth-promoting effects tied to the rest of the HGH molecule, because those effects come from a different region of the protein than the fat-metabolizing region. This matters because full-length growth hormone use carries real, well-documented risks: elevated blood sugar, insulin resistance, joint and soft-tissue swelling, and in supraphysiologic doses, organ growth. The fragment strategy tried to keep the metabolic benefit and cut the baggage. Whether that clean separation holds up perfectly in practice is a narrower question than most sellers imply, and the honest answer is that the human obesity trial program was not large enough or long enough to fully characterize this across diverse populations. What we do have is reassurance on a different but related front: a 2013 study in Drug Testing and Analysis found that AOD-9604 does not interfere with the WADA hGH isoform immunoassay used in anti-doping testing, meaning it does not get picked up or falsely trigger the standard test used to detect banned growth hormone use in athletes ^[7]. That is a useful, specific, well-documented fact. It is not the same as a full safety profile across a completed drug development program, which AOD-9604 never finished.

Is AOD-9604 approved by the FDA or any regulator?

No. AOD-9604 has not been approved by the FDA, the European Medicines Agency, or Australia's TGA for any use, including obesity. It does not appear in the FDA's Drugs@FDA database of approved drug products ^[6]. It also sits in a gray zone under U.S. compounding law. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) may only use bulk drug substances that are FDA-approved, subject to a USP or NF monograph, or on the FDA's 503A bulk drug substances list ^[8][9]. The FDA maintains that bulk drug substances list under 21 CFR 216.23, and a parallel list for outsourcing facilities under 21 CFR 216.24 for 503B compounding ^[10][11]. AOD-9604 does not appear on the FDA's current published nominations list for bulk substances eligible for compounding ^[12]. Practically, this means AOD-9604 sold in the U.S. mostly moves through the research-chemical channel, labeled "not for human consumption," or through compounding pharmacies operating in a regulatory gray area that the FDA has not formally blessed. Anyone buying it should understand that regulatory gap going in, not discover it later. See our aod 9604 peptide for sale guide for how sourcing actually plays out and what questions to ask a supplier.

How does AOD-9604 compare to GLP-1 drugs like semaglutide?

There is no fair comparison here on efficacy data, and being straight about that is the whole point of this article. GLP-1 receptor agonists went through large, multi-year Phase III trials with thousands of patients and produced weight loss in the range of roughly 15 percent of body weight over about 68 weeks in the key semaglutide obesity trial, a result strong enough to win FDA approval and get folded into major medical society guidance. That data is public, replicated, and listed in the FDA's own approved drug database ^[6]. AOD-9604's Phase IIb obesity program produced a much smaller, less consistent signal that did not clear the bar for an approval submission ^{[1][5][2][3][4]}. That is not a close call. If your priority is the strongest evidence-backed option for meaningful fat loss, GLP-1 drugs currently have a far deeper and more convincing human trial record than AOD-9604 does.

This is not an argument that AOD-9604 is useless as a research compound or that the underlying biochemistry is fraudulent. It is an argument that if someone tells you AOD-9604 is comparable to modern obesity pharmacotherapy, they are not describing the trial record accurately.

Why do people still talk about AOD-9604 for fat loss and injury recovery?

Two separate stories get blended together in AOD-9604 marketing, and untangling them helps explain why the peptide has staying power despite the weak obesity data. The first story is the original one: an anti-obesity drug candidate that underperformed in human trials. That story is mostly over, at least for the pharmaceutical development path. The second story is newer and different: AOD-9604 and related growth-hormone-derived peptides have drawn interest in orthopaedic and sports-medicine research for tissue and joint applications, separate from the fat-loss angle. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics generally, including applications, challenges, and open questions for compounds in this broader class ^[13]. A parallel 2026 review in Sports Medicine covers safety and efficacy questions for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[14]. Neither of those 2026 reviews is a dedicated AOD-9604 obesity efficacy trial, and neither overturns the original weak weight-loss data. What they show is that research interest in this peptide family has shifted somewhat toward musculoskeletal and recovery contexts, which is a genuinely different question from "does this melt fat." If a seller cites orthopaedic peptide research to justify a fat-loss claim, that is a mismatch worth noticing.

Does AOD-9604 show up on drug tests, and is it banned in sport?

AOD-9604 has been on WADA's prohibited list as a growth hormone fragment, and detecting it in doping control has required its own analytical work separate from standard hGH testing. A 2013 study confirmed AOD-9604 does not interfere with the WADA hGH isoform immunoassay, meaning it won't falsely trigger that particular test, but that is a statement about assay interference, not about whether the substance itself is permitted ^[7]. Because AOD-9604 is a small peptide fragment, it falls into a detection category that standard hGH tests were not originally built to catch well. Research on analytical methods for detecting peptide drugs and analogs in doping control has specifically flagged small peptides and emerging therapeutics as a moving target for anti-doping labs, requiring dedicated mass spectrometry approaches ^[15][4]. A 2016 method paper in the Journal of Separation Science describes a direct urine injection, liquid chromatography, and ion mobility mass spectrometry approach built in part to catch peptides under 2 kDa, a size range that includes fragments like AOD-9604 ^[10]. A 2014 review in Expert Review of Proteomics likewise discusses the ongoing challenge of detecting peptidic drugs, drug candidates, and their analogs in sports doping programs ^[4]. Bottom line for athletes: AOD-9604 is treated as a prohibited substance in tested sport, and the fact that it evades one specific old-style immunoassay does not mean it evades modern anti-doping detection generally. Testing methods have moved specifically to close that gap.

What does the honest fat-loss verdict look like for AOD-9604?

The honest verdict is that AOD-9604 is a scientifically interesting fragment with a real, biologically plausible fat-metabolism mechanism, but a human trial record that never delivered a convincing, placebo-beating weight-loss result, and that record has not materially changed since the mid-2000s ^{[1][5][2][3][4]}. It was never approved by the FDA for obesity or any other use, it does not appear in Drugs@FDA ^[6], and it is not on the FDA's 503A bulk compounding list ^[12]. Anyone selling it with confident claims of significant fat loss is going well beyond what the human trial data actually shows. If you are researching this because you want a fat-loss intervention with strong human evidence behind it, the honest recommendation is to look at approved obesity pharmacotherapy first and treat AOD-9604 as an unproven research compound, not a substitute. If you are researching it anyway, out of interest in the mechanism or because you're already committed to trying it, go in with clear eyes about the placebo-separation problem and the lack of regulatory approval. For dosing patterns reported in the research and gray-market literature (not a clinical recommendation), see our aod 9604 dosage guide, our aod 9604 dosage calculator, and reconstitution mechanics in aod 9604 how to reconstitute. Side effect reports from users and the limited trial safety data are covered in aod 9604 peptide side effects.

Where can you find AOD-9604 through a provider-reviewed source?

If, after weighing the trial record, you still want to pursue AOD-9604 through a legitimate channel rather than an unregulated research-chemical vendor, the safer path is a provider-reviewed route rather than a direct-to-consumer gray-market purchase. AOD-9604 Co reviews sourcing options and points readers toward fulfillment through a licensed pharmacy partner, rather than compounding or manufacturing anything itself. That distinction matters. A provider-reviewed pathway means a clinician has looked at your situation and a licensed pharmacy is handling fulfillment, which is a meaningfully different risk profile than an unlabeled vial from an anonymous website. It does not change the underlying trial-evidence picture, but it does change the quality-control and legal-standing picture. Whoever you buy from, ask directly whether the product is coming from a facility operating under 503A or 503B rules, and understand that AOD-9604's absence from the FDA's bulk substances list ^[12] means this whole category sits outside the normal FDA-approved-drug pathway, regardless of who sells it to you.

Frequently asked questions

Did AOD-9604 pass its clinical trials?

AOD-9604 completed Phase I and Phase IIb human trials for obesity, but the weight-loss results did not separate convincingly from placebo. It was never approved by the FDA or any major regulator for obesity or any other use, and it does not appear in the FDA's Drugs@FDA database ^[13].

Is AOD-9604 FDA approved?

No. AOD-9604 has never been approved by the FDA for any indication. It is not listed in the Drugs@FDA approved products database ^[13], and it does not appear on the FDA's current bulk drug substances list for 503A pharmacy compounding ^[15].

How does AOD-9604 work for fat loss, in theory?

AOD-9604 is a fragment of human growth hormone corresponding to amino acids 176-191, the region thought to drive HGH's fat-metabolizing (lipolytic) effect, without the growth-promoting or blood-sugar effects tied to the rest of the molecule ^[1]. The theory is sound biochemistry; the human trial results did not confirm a strong fat-loss effect.

Does AOD-9604 raise IGF-1 levels?

The fragment was specifically designed to avoid the IGF-1-raising, growth-promoting activity of full-length HGH, since that activity maps to a different part of the molecule than the fat-metabolizing region ^[1]. The human obesity trial program was not large enough to fully characterize this across all populations.

Is AOD-9604 detectable on a WADA drug test?

A 2013 study found AOD-9604 does not interfere with the WADA hGH isoform immunoassay ^[4], meaning it won't falsely trigger that specific older test. Newer mass spectrometry methods built for small peptides under 2 kDa are specifically designed to catch fragments like AOD-9604 ^[6][10].

How does AOD-9604 compare to semaglutide or other GLP-1 drugs for weight loss?

GLP-1 drugs have large, replicated Phase III trials and FDA approval for weight loss. AOD-9604's obesity trial program stalled after Phase IIb with weak placebo separation and was never submitted for approval ^{[1][5][7][8][9]}. On trial evidence alone, GLP-1 drugs are far better supported.

Why did AOD-9604's obesity trials fail?

The trials did not fail in the sense of causing harm; they failed in the sense of not showing a weight-loss effect large or consistent enough to beat placebo by a meaningful margin, which is the bar regulators require before approving an obesity drug ^[5][7][8][9].

Is AOD-9604 legal to buy in the United States?

It occupies a gray zone. It's not FDA-approved, and it's not on the FDA's 503A bulk compounding list ^[15], so it falls outside the normal approved-drug or standard-compounding pathways. Much of what's sold online is labeled research-use-only rather than for human use.

What is AOD-9604 actually made of?

It's a synthetic peptide fragment, amino acids 176-191 of the human growth hormone sequence, isolated because that segment is believed to carry HGH's fat-metabolizing activity separate from its growth-promoting effects ^[1].

Has AOD-9604 been studied for anything besides fat loss?

Yes. More recent 2026 reviews cover peptide therapies, including AOD-9604's broader class, in orthopaedic and musculoskeletal injury contexts ^[2][3]. That research is separate from the original obesity trials and doesn't change the weak weight-loss trial record.

Does AOD-9604 cause the same side effects as HGH injections?

The fragment was designed to avoid HGH's classic side effects like elevated blood sugar and joint swelling, because those come from a different part of the molecule ^[1]. But the human trial program was too limited to fully rule out risks across long-term or high-dose use.

Can a compounding pharmacy legally make AOD-9604?

Under 21 U.S.C. 353a, 503A compounding requires the bulk substance to be FDA-approved, covered by a USP/NF monograph, or on the FDA's 503A bulks list under 21 CFR 216.23 ^[10][12][14]. AOD-9604 is not currently on that list ^[15], which puts standard 503A compounding of it on uncertain legal footing.

What's the single most important fact about AOD-9604's trial history?

In human obesity trials, AOD-9604's weight-loss effect did not separate convincingly from placebo, and the compound never reached FDA approval or Phase III completion for obesity ^{[1][5][7][8][9]}. That is the central, unresolved fact anyone researching this peptide needs to know first.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's development as an HGH-derived fat-metabolizing fragment for obesity, covering its metabolic rationale.
2. PubMed, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026): Reviews therapeutic peptides including AOD-9604's class in orthopaedic applications, challenges, and future directions.
3. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
4. PubMed, Drug Testing and Analysis (2013): Confirms AOD-9604 does not interfere with the WADA hGH isoform immunoassay used in anti-doping testing.
5. PubMed, Current Opinion in Investigational Drugs (2006): Reviews the obesity drug development landscape of the mid-2000s that AOD-9604 was part of, most of which did not reach market.
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Covers analytical approaches for detecting emerging therapeutics and non-approved drugs, including small peptides, in doping controls.
7. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateway summary of clinical trials in development, covering the era of AOD-9604's obesity trial program.
8. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Second gateway summary of clinical trials in development covering the same period of AOD-9604's obesity program.
9. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): Later gateway summary of clinical trials in development, covering the continuation of AOD-9604's obesity program status.
10. PubMed, Journal of Separation Science (2016): Describes a direct urine injection LC-ion mobility mass spectrometry method built to screen peptides under 2 kDa, including fragments like AOD-9604.
11. PubMed, Expert Review of Proteomics (2014): Discusses ongoing challenges detecting peptidic drugs and drug candidates, including analogs, in sports doping control.
12. eCFR, 21 CFR 216.23: Establishes the FDA's final 503A bulk drug substances list governing what compounders may legally use.
13. eCFR, 21 CFR 216.24: Establishes the parallel FDA 503B bulk drug substances list for outsourcing facilities.
14. Cornell Law, 21 U.S.C. 353a: Sets the federal legal requirements for pharmacy compounding under Section 503A, including permitted bulk substances.
15. FDA, Drugs@FDA database: Official FDA database of approved drug products, in which AOD-9604 does not appear.
16. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains FDA's criteria and process for bulk substances eligible for 503A compounding.
17. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Current FDA list of nominated bulk drug substances, on which AOD-9604 does not currently appear as an approved 503A substance.